Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2026. Total revenue increased 24 per cent at CER (constant exchange rates), 11 per cent at actual rates, ...

When drugmakers look to build out certain therapeutic areas, there are two options: Create your own and buy someone else’s. For Stockholm-based Sobi, getting a leg up in hematology meant making an ...

Swedish Orphan Biovitrum, also known as Sobi, reported first-quarter revenue in line with expectations, while adjusted ...

STOCKHOLM, Feb. 18, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today hosts its Capital Markets Day, where senior management will provide an update on the company's strategy and outline its new mid-term ...

Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and Sustainability report for 2025, outlining the company’s progress in unlocking the potential of breakthrough innovations and ...

Revenue is anticipated to grow at low double-digit percentage at CER The adjusted EBITA margin is anticipated to be in the mid 30s percentage of revenue 1. Alternative Performance Measures (APMs). 2.

Sobi, which currently has a drug under FDA review as a later line of therapy for gout, is paying $950 million to acquire Arthrosi Therapeutics, a startup with a gout drug candidate in Phase 3 ...

Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year revenue was ...

CTI Biopharma has something many biotech companies aspire to achieve—revenue. Sales of its approved cancer drug are growing, but commercialization comes with costs as does development of the molecule ...

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its report for the first quarter of 2026. First Quarter 2026Total revenue increased 24 ...